Our results show that the tumor suppression activity of p53 can be unleashed by inhibition of the USP2/VPRBP pathway, and that this mode of p53 activation should circumvent the toxicities that have arisen in clinical trials of Mdm2 inhibitors. This evidence concerns the gene MDM2 and neoplasm.